|
Home | Issues | eMJA shop | Classifieds | Contact | More... | Topics | Search | Login | Buy full access |
→ Contents list for this issue
→ More articles on Ophthalmology
→ More articles on Infectious diseases and parasitology
→ Search PubMed for related articles
Click to Login
Hide the Login Box
To the Editor: The Therapeutic Goods Association (TGA) has informed Australian eye banks that nucleic acid testing (NAT) of donor sera will be required in addition to routine serological tests for hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV. NAT can detect viral genome in the window period between infection and the appearance of antigen or antibody, and is to commence in Australia as soon as possible. However, we believe the benefit of NAT would be small and the cost considerable. Importantly, it would be likely to have an adverse effect on the availability of donor corneas for transplantation.
Login or register to purchase access to the full article
|
|
Home | Issues | eMJA shop | Terms of use | Classifieds | More... | Contact | Topics | Search |
©The Medical Journal of Australia 2009 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377